Company intelligence / Profile preview

NED Biosystems

Cambridge, Massachusetts, United Statesnedbiosystems.com ↗

Ownership: Private
Development stage: Phase 1

Overview

NED-170 has allowed the first 27 observational patients (mostly heavily pre-treated, late-stage IV) extended survival with some achieving and sustaining no evidence of disease[5]. A Phase 1b/2 clinical trial for NED-170 is being conducted in collaboration with the Institute for Systems Biology[3].

Therapeutic areas: OncologyInfectious Diseases
Modalities: Repurposed oral agentsnutraceuticals
Industry: Biotech

Drug pipeline

2 assets

NED-260

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Institute for Systems Biology (ISB)

Beyond the preview

Go deeper on NED Biosystems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NED Biosystems.

Explore the full profile